Stanley Family Foundation
1
21M
1
0.02
1
1
- Areas of investment
Summary
Stanley Family Foundation appeared to be the Corporate Investor, which was created in 1956. The leading representative office of defined Corporate Investor is situated in the Muscatine. The fund was located in North America if to be more exact in United States.
The standard case for the fund is to invest in rounds with 3 partakers. Despite the Stanley Family Foundation, startups are often financed by MVM Life Science Partners, Novartis Venture Fund, Clarus Ventures. The meaningful sponsors for the fund in investment in the same round are Takeda Ventures, Clarus Ventures. In the next rounds fund is usually obtained by Teva Pharmaceutical Industries.
For fund there is no match between the country of its foundation and the country of its the most frequent investments - United Kingdom. Besides, a startup requires to be at the age of 6-10 years to receive the investment from the fund. Among the most popular portfolio startups of the fund, we may highlight Heptares Therapeutics. Among the most successful fund investment fields, there are Biotechnology, Pharmaceutical.
The increased amount of exits for fund were in 2015. The top activity for fund was in 2013. The common things for fund are deals in the range of 10 - 50 millions dollars. The fund is constantly included in less than 2 investment rounds annually.
Investments analytics
Analytics
- Total investments
- 1
- Lead investments
- 1
- Exits
- 1
- Rounds per year
- 0.02
- Investments by industry
- Pharmaceutical (1)
- Therapeutics (1)
- Biotechnology (1)
- Investments by region
-
- United Kingdom (1)
- Peak activity year
- 2013
Discover reliable insights
Leverage validated data, identify key contacts and secure funding opportunities for your business.Quantitative data
- Avg. startup age at the time of investment
- 14
- Avg. valuation at time of investment
- 400M
- Group Appearance index
- 1.00
- Avg. company exit year
- 8
- Avg. multiplicator
- 6.50
Need more data?
Get access to full data about investors, including their team, contact information, and historic data.
Latest deals
| Company name | Deal date | Industry | Deal stage | Deal size | Location |
|---|---|---|---|---|---|
| Heptares Therapeutics | 27 Jun 2013 | Biotechnology, Pharmaceutical, Therapeutics | Early Stage Venture | 21M | United Kingdom, England |
At Unicorn Nest, we combine cutting-edge technology with human expertise to build one of the most reliable venture capital databases in the market. Our process begins with automated AI-enhanced data collection, leveraging the full potential of Large Language Models (LLMs).
Later, our team of analysts takes it further with manual verification, using proprietary tools for data cleaning and validation to ensure accuracy and reliability. We cross-check and enhance our findings through press and media monitoring, integrating information from trusted news outlets and venture capital aggregators. Finally, we stay ahead of the curve by monitoring social networks like LinkedIn and X.com.